Abstract | INTRODUCTION: AREAS COVERED: A summary of the preclinical studies and of studies carried out in patients with chronic liver disease with eltrombopag are presented in this paper. Data are based on abstracts from journal articles and international conferences found in a PubMed search of literature published up to November 2012. EXPERT OPINION:
|
Authors | Edoardo G Giannini, Nezam H Afdhal |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 14
Issue 5
Pg. 669-78
(Apr 2013)
ISSN: 1744-7666 [Electronic] England |
PMID | 23452139
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Benzoates
- Hematologic Agents
- Hydrazines
- Pyrazoles
- Receptors, Thrombopoietin
- MPL protein, human
- eltrombopag
|
Topics |
- Animals
- Benzoates
(adverse effects, pharmacokinetics, therapeutic use)
- Chronic Disease
- Hematologic Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Humans
- Hydrazines
(adverse effects, pharmacokinetics, therapeutic use)
- Liver Diseases
(blood, complications, drug therapy)
- Pyrazoles
(adverse effects, pharmacokinetics, therapeutic use)
- Receptors, Thrombopoietin
(agonists, metabolism)
- Thrombocytopenia
(blood, drug therapy, etiology)
- Thrombopoiesis
(drug effects)
- Treatment Outcome
|